Effects of Physical Tracing on Estimates of Loss to Follow-Up, Mortality and Retention in Low and Middle Income Country Antiretroviral Therapy Programs: A Systematic Review

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  McMahon, James H ^a,b   Elliott, Julian H ^a,c,d   Hong, Steven Y ^b,e   Bertagnolio, Silvia ^f   Jordan, Michael R ^b,e  

^a ALFRED HOSPITAL   (Australia)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MONASH UNIVERSITY   (Australia)

^d BURNET INSTITUTE   (Australia)

^e TUFTS MEDICAL CENTER   (United States)

^f UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; FEMALE; FOLLOW UP; HEALTH PROGRAM; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTERNATIONAL COOPERATION; MALE; MORTALITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COMPLIANCE; SYSTEMATIC REVIEW; TREATMENT DURATION;

ANTI-HIV AGENTS; DEVELOPING COUNTRIES; HEALTH BEHAVIOR; HIV INFECTIONS; HUMANS; INCOME; LOST TO FOLLOW-UP;

EID: 84873720845     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056047     Document Type: Article

References (66)

1. WHO (2011) Towards universal access: scaling up priority HIV/AIDS interventions in the health sector: progress report 2011. Geneva: World Health Organization.
2. Weidle PJ, Malamba S, Mwebaze R, Sozi C, Rukundo G, et al. (2002) Assessment of a pilot antiretroviral drug therapy programme in Uganda: patients' response, survival, and drug resistance. Lancet 360: 34-40.
3. Severe P, Leger P, Charles M, Noel F, Bonhomme G, et al. (2005) Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med 353: 2325-2334.
4. Coetzee D, Hildebrand K, Boulle A, Maartens G, Louis F, et al. (2004) Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS 18: 887-895.
5. WHO (2010) HIV Drug Resistance Early Warning Indicators.World Health Organization indicators to monitor HIV drug resistance prevention at antiretroviral treatment sites. June 2010 Update. Geneva: World Health Organization.
6. WHO (2006) Patient monitoring guidelines for HIV care and antiretroviral therapy. Integrated management of adolescent and adult illness/ Integrated management of childhood illness. Geneva: World Health Organization.
7. UNAIDS (2009) Monitoring the Declaration of Commitment on HIV/AIDS: guidelines on construction of core indicators: 2010 reporting. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS).
8. PEPFAR (2009) Next Generation Indicator Reference Guide. Version 1.1. The President's Emergency Plan for AIDS Relief. Department of Health and Human Services. United States Government.
9. Brinkhof MW, Pujades-Rodriguez M, Egger M, Brinkhof MWG, Pujades-Rodriguez M, et al. (2009) Mortality of patients lost to follow-up in antiretroviral treatment programmes in resource-limited settings: systematic review and meta-analysis. PLoS ONE [Electronic Resource] 4: e5790.
10. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, et al. (2011) Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 365: 493-505.
11. Parienti JJ, Massari V, Descamps D, Vabret A, Bouvet E, et al. (2004) Predictors of virologic failure and resistance in HIV-infected patients treated with nevirapine- or efavirenz-based antiretroviral therapy. Clin Infect Dis 38: 1311-1316.
12. Oyugi JH, Byakika-Tusiime J, Ragland K, Laeyendecker O, Mugerwa R, et al. (2007) Treatment interruptions predict resistance in HIV-positive individuals purchasing fixed-dose combination antiretroviral therapy in Kampala, Uganda. AIDS 21: 965-971.
13. Harries AD, Zachariah R, Lawn SD, Rosen S, (2010) Strategies to improve patient retention on antiretroviral therapy in sub-Saharan Africa. Trop Med Int Health 15Suppl 1: 70-75.
14. Fox MP, Rosen S, (2010) Patient retention in antiretroviral therapy programs up to three years on treatment in sub-Saharan Africa, 2007-2009: systematic review. Tropical Medicine & International Health 15Suppl 1: 1-15.
15. Cornell M, Grimsrud A, Fairall L, Fox MP, van Cutsem G, et al. (2010) Temporal changes in programme outcomes among adult patients initiating antiretroviral therapy across South Africa, 2002-2007. AIDS 24: 2263-2270.
16. Geng EH, Bangsberg DR, Musinguzi N, Emenyonu N, Bwana MB, et al. (2010) Understanding reasons for and outcomes of patients lost to follow-up in antiretroviral therapy programs in Africa through a sampling-based approach. Journal of Acquired Immune Deficiency Syndromes: JAIDS 53: 405-411.
17. Tassie J-M, Malateste K, Pujades-Rodriguez M, Poulet E, Bennett D, et al. (2010) Evaluation of three sampling methods to monitor outcomes of antiretroviral treatment programmes in low- and middle-income countries. PLoS ONE [Electronic Resource] 5: e13899.
18. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, et al. (2006) Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 367: 817-824.
19. Rosen S, Fox MP, Gill CJ, (2007) Patient retention in antiretroviral therapy programs in sub-Saharan Africa: a systematic review. PLoS Medicine/ Public Library of Science 4: e298.
20. Gupta A, Nadkarni G, Yang WT, Chandrasekhar A, Gupte N, et al. (2011) Early mortality in adults initiating antiretroviral therapy (ART) in low- and middle-income countries (LMIC): a systematic review and meta-analysis. PLoS One 6: e28691.
21. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R, (2008) Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 22: 1897-1908.
22. Hawkins C, Achenbach C, Fryda W, Ngare D, Murphy R, (2007) Antiretroviral durability and tolerability in HIV-infected adults living in urban Kenya. J Acquir Immune Defic Syndr 45: 304-310.
23. Laurent C, Meilo H, Guiard-Schmid JB, Mapoure Y, Noel JM, et al. (2005) Antiretroviral therapy in public and private routine health care clinics in Cameroon: lessons from the Douala antiretroviral (DARVIR) initiative. Clin Infect Dis 41: 108-111.
24. Wools-Kaloustian K, Kimaiyo S, Diero L, Siika A, Sidle J, et al. (2006) Viability and effectiveness of large-scale HIV treatment initiatives in sub-Saharan Africa: experience from western Kenya. AIDS 20: 41-48.
25. Hingankar N, Thorat S, Deshpande A, Rajasekaran S, Chandrasekar C, et al. (2012) Initial virologic response and HIV drug resistance among HIV-1 infected individuals initiating first-line antiretroviral therapy at two clinics in Chennai and Mumbai India. Clin Infect Dis 54: S348-354.
26. Ugbena R, Aberle-Grasse J, Diallo K, Bassey O, Jelpe T, et al. (2012) Virological response and HIV-1 drug resistance 12 months after antiretroviral therapy initiation at two clinics in Nigeria Clin Infect Dis. 54: S375-379.
27. Palombi L, Marazzi MC, Guidotti G, Germano P, Buonomo E, et al. (2009) Incidence and predictors of death, retention, and switch to second-line regimens in antiretroviral- treated patients in sub-Saharan African Sites with comprehensive monitoring availability. Clinical Infectious Diseases 48: 115-122.
28. Vella V, Govender T, Dlamini S, Taylor M, Moodley I, et al. (2010) Retrospective study on the critical factors for retaining patients on antiretroviral therapy in KwaZulu-Natal, South Africa. Journal of Acquired Immune Deficiency Syndromes: JAIDS 55: 109-116.
29. Zachariah R, Teck R, Buhendwa L, Fitzerland M, Labana S, et al. (2007) Community support is associated with better antiretroviral treatment outcomes in a resource-limited rural district in Malawi. Trans R Soc Trop Med Hyg 101: 79-84.
30. Oleckno W (2008) Basic Measures of Occurrence in Epidemiology. Epidemiology Concepts and Methods. Long Grove: Waveland Press Inc. 98-99.
31. Barth RE, van der Meer JT, Hoepelman AI, Schrooders PA, van de Vijver DA, et al. (2008) Effectiveness of highly active antiretroviral therapy administered by general practitioners in rural South Africa. Eur J Clin Microbiol Infect Dis 27: 977-984.
32. Bisson GP, Frank I, Gross R, Lo Re V, 3rd, Strom JB, et al (2006) Out-of-pocket costs of HAART limit HIV treatment responses in Botswana's private sector. AIDS 20: 1333-1336.
33. Bisson GP, Gaolathe T, Gross R, Rollins C, Bellamy S, et al. (2008) Overestimates of survival after HAART: implications for global scale-up efforts. PLoS ONE [Electronic Resource] 3: e1725.
34. Charalambous S, Innes C, Muirhead D, Kumaranayake L, Fielding K, et al. (2007) Evaluation of a workplace HIV treatment programme in South Africa. AIDS 21Suppl 3: S73-78.
35. Chi BH, Cantrell RA, Zulu I, Mulenga LB, Levy JW, et al. (2009) Adherence to first-line antiretroviral therapy affects non-virologic outcomes among patients on treatment for more than 12 months in Lusaka, Zambia. International Journal of Epidemiology 38: 746-756.
36. Chung MH, Kohler P, Attwa M, Thiga J, John-Stewart GC, et al. (2010) Comparing clinic retention between residents and nonresidents of Kibera, Kenya. Journal of Acquired Immune Deficiency Syndromes: JAIDS 53: 422-424.
37. Collini P, Schwab U, Sarfo S, Obeng-Baah J, Norman B, et al. (2009) Sustained immunological responses to highly active antiretroviral therapy at 36 months in a Ghanaian HIV cohort. Clinical Infectious Diseases 48: 988-991.
38. Culbert H, Tu D, O'Brien DP, Ellman T, Mills C, et al. (2007) HIV treatment in a conflict setting: outcomes and experiences from Bukavu, Democratic Republic of the Congo. PLoS Med 4: e129.
39. DeSilva MB, Merry SP, Fischer PR, Rohrer JE, Isichei CO, et al. (2009) Youth, unemployment, and male gender predict mortality in AIDS patients started on HAART in Nigeria. AIDS Care 21: 70-77.
40. Etard JF, Ndiaye I, Thierry-Mieg M, Gueye NF, Gueye PM, et al. (2006) Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS 20: 1181-1189.
41. Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, et al. (2006) Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment. Lancet 367: 1335-1342.
42. Karcher H, Omondi A, Odera J, Kunz A, Harms G, (2007) Risk factors for treatment denial and loss to follow-up in an antiretroviral treatment cohort in Kenya. Trop Med Int Health 12: 687-694.
43. Marston BJ, Macharia DK, Nga'nga L, Wangai M, Ilako F, et al. (2007) A program to provide antiretroviral therapy to residents of an urban slum in nairobi, kenya. J Int Assoc Physicians AIDS Care (Chic Ill) 6: 106-112.
44. Moore E, Beadsworth MBJ, Chaponda M, Mhango B, Faragher B, et al. (2010) Favourable one-year ART outcomes in adult Malawians with hepatitis B and C co-infection. Journal of Infection 61: 155-163.
45. Mutevedzi PC, Lessells RJ, Heller T, Barnighausen T, Cooke GS, et al. (2010) Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes? Bulletin of the World Health Organization 88: 593-600.
46. Thai S, Koole O, Un P, Ros S, De Munter P, et al. (2009) Five-year experience with scaling-up access to antiretroviral treatment in an HIV care programme in Cambodia. Tropical Medicine & International Health 14: 1048-1058.
47. Toure S, Kouadio B, Seyler C, Traore M, Dakoury-Dogbo N, et al. (2008) Rapid scaling-up of antiretroviral therapy in 10,000 adults in Cote d'Ivoire: 2-year outcomes and determinants. AIDS 22: 873-882.
48. Wester CW, Kim S, Bussmann H, Avalos A, Ndwapi N, et al. (2005) Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr 40: 336-343.
49. Somi G, Arthur G, Gongo R, Senkoro K, T Kellogg T, et al. (2011) 24-Month Outcomes for Adults in Tanzania's National ART Program from 2004 to 2009: Success Maintained during Scale-up, but Should Services Be More Youth Friendly? CROI 2011 Paper #1019.
50. Ehmer J, Truniger C, Waldegg G, Mussa I, Mushi A, et al. (2009) Characteristics and outcomes of HIV-infected patients starting HAART in rural treatment programmes in four sub-Saharan African countries International AIDS Society- Abstract- MOPED045.
51. Cortes C, Beltran C, Wolff M (2010) Rate of Mortality, Loss to Follow-up, Viral Suppression, Immune Recovery, and Maintenance of Initial Antiretroviral Regimen at 4 Years: 3045 Chilean Patients. CROI 2010 Paper #523.
52. Chinh N, Quang V, Thi Tuyet Nhung V, Colby D (2010) First-line ART Outcomes in HIV-infected Adults in Ho Chi Minh City, Vietnam. CROI 2010 Paper #517.
53. Bertagnolio S, Kelley K, Saadani Hassani A, Obeng-Aduasare Y, Jordan M (2011) Surveillance of Transmitted and Acquired HIV Drug Resistance Using WHO Surveys in Resource-limited Settings. CROI 2011 Paper # 52.
54. Balestre E, Lokossue A, Eholié S, Sow P, Charurat M, et al. (2011) Effect of Age on Immunological Response in the First Year of HAART in HIV-1-infected Adults, IeDEA West Africa Collaboration. CROI 2011 Paper # 272.
55. Auld A, Mbofana F, Shiraishi R, Sanchez M, Alfredo C, et al. (2010) Treatment outcomes of Mozambique's adult antiretroviral therapy program- earlier treatment and co-trimoxazole are important. International AIDS Society- Abstract- TUAB0204.
56. May M, Boulle A, Phiri S, Messou E, Myer L, et al. (2010) Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 376: 449-457.
57. Bedelu M, Ford N, Hilderbrand K, Reuter H, Bedelu M, et al. (2007) Implementing antiretroviral therapy in rural communities: the Lusikisiki model of decentralized HIV/AIDS care. Journal of Infectious Diseases 196Suppl 3: S464-468.
58. Hong SY, Jonas A, Dumeni E, Badi A, Pereko D, et al. (2010) Population-based monitoring of HIV drug resistance in Namibia with early warning indicators. Journal of Acquired Immune Deficiency Syndromes: JAIDS 55: 27-31.
59. O'Brien DP, Mills C, Hamel C, Ford N, Pottie K, (2009) Universal access: the benefits and challenges in bringing integrated HIV care to isolated and conflict affected populations in the Republic of Congo. Confl Health 3: 1.
60. Johannessen A, Naman E, Ngowi BJ, Sandvik L, Matee MI, et al. (2008) Predictors of mortality in HIV-infected patients starting antiretroviral therapy in a rural hospital in Tanzania. BMC Infect Dis 8: 52.
61. Assefa Y, Van Damme W, Mariam DH, Kloos H, (2010) Toward universal access to HIV counseling and testing and antiretroviral treatment in Ethiopia: looking beyond HIV testing and ART initiation. AIDS Patient Care & Stds 24: 521-525.
62. Sharma SK, Dhooria S, Prasad KT, George N, Ranjan S, et al. (2010) Outcomes of antiretroviral therapy in a northern Indian urban clinic. Bulletin of the World Health Organization 88: 222-226.
63. Palella FJ Jr, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, et al. (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860.
64. Das M, Chu PL, Santos GM, Scheer S, Vittinghoff E, et al. (2010) Decreases in community viral load are accompanied by reductions in new HIV infections in San Francisco. PLoS One 5: e11068.
65. Montaner JS, Wood E, Kerr T, Lima V, Barrios R, et al. (2010) Expanded highly active antiretroviral therapy coverage among HIV-positive drug users to improve individual and public health outcomes. J Acquir Immune Defic Syndr 55Suppl 1: S5-9.
66. Forgione L, Torzian L (2012) Trends in community viral load, new diagnoses, and estimated incidence of HIV, New York City, 2005-2009. Abstract #1123. CROI. Seattle, USA.